How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 66.0 | 66.0 | 66.3 | 65.6 | 65.6 | 64.4 | -1.6 |
| Healthcare | 28.7 | 28.7 | 28.0 | 28.3 | 28.3 | 29.3 | +0.6 |
| Chemicals | 4.0 | 4.0 | 5.1 | 4.9 | 4.9 | 5.2 | +1.2 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 13.73% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| MAXHEALTH | Healthcare | 5.99% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| JBCHEPHARM | Pharma | 5.45% | 9 | 7 | 2 | 5 | 1 | 1/2 | +18.6% |
| DIVISLAB | Pharma | 5.33% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| ACUTAAS | Chemicals | 5.20% | 8 | 10 | 2 | 5 | 1 | 0/2 | +43.1% |
| CIPLA | Pharma | 4.32% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| FORTIS | Healthcare | 4.02% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| MANKIND | Pharma | 3.38% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
| KIMS | Healthcare | 3.09% | 7 | 3 | 7 | 4 | 1 | 0/2 | +19.2% |
| SAILIFE | Healthcare | 2.91% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| APOLLOHOSP | Healthcare | 2.56% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| AJANTPHARM | Pharma | 2.37% | 8 | 10 | 1 | 4 | 3 | 0/2 | +14.6% |
| AUROPHARMA | Pharma | 2.33% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
| LUPIN | Pharma | 2.32% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| ANTHEM | Pharma | 2.27% | 7 | 10 | 3 | 5 | 2 | 0/2 | -2.3% |
| LAURUSLABS | Pharma | 2.24% | 8 | 9 | 4 | 4 | 1 | 0/2 | +34.0% |
| GLAND | Pharma | 2.21% | 9 | 8 | 6 | 6 | 4 | 0/2 | +38.5% |
| JUBLPHARMA | Pharma | 1.93% | 5 | 2 | 3 | 6 | 6 | 0/2 | +5.5% |
| ZYDUSLIFE | Pharma | 1.64% | 10 | 10 | 10 | 10 | 6 | 1/2 | +23.3% |
| GLENMARK | Pharma | 1.62% | 6 | 9 | 10 | 4 | 3 | 0/2 | +1.5% |
| ALKEM | Pharma | 1.56% | 9 | 8 | 8 | 10 | 6 | 1/2 | +0.5% |
| EMCURE | Pharma | 1.49% | 8 | 10 | 5 | 5 | 3 | 0/2 | +9.8% |
| RAINBOW | Healthcare | 1.46% | 10 | 7 | 2 | 5 | 4 | 1/2 | +15.3% |
| LALPATHLAB | Healthcare | 1.07% | 10 | 8 | 7 | 1 | 3 | 0/2 | +16.6% |
Performance · 2.6y
Over the last 2.6 years ₹100 in the fund grew to ₹161 (+61%), vs ₹120 for Nifty 500 (+20%) and ₹112 for Nifty 50 (+12%). Its relative-strength line ended at 144 vs Nifty 50 and 134 vs Nifty 500 — above 100, sustained outperformance.